| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
The primary targets of Meconine are not well-defined as a specific receptor or enzyme target, as it is primarily used as a forensic and analytical standard. As a metabolite of noscapine, it is formed through metabolic pathways involving O-demethylation and lactone formation. It may serve as a biomarker for noscapine exposure or illicit opiate use. These characteristics make it relevant for forensic toxicology and drug metabolism research.
|
|---|---|
| ln Vitro |
In vitro, Meconine is used primarily as a reference standard and analytical marker. It is employed in the development and validation of analytical methods for the detection of noscapine and its metabolites in biological samples. The compound is used in LC-MS/MS and GC-MS methods for forensic and clinical toxicology applications. Its stability and recovery in various biological matrices are characterized. These in vitro activities support its use in forensic toxicology, clinical chemistry, and drug metabolism research.
|
| ln Vivo |
In vivo, Meconine is formed as a metabolite of noscapine, an opium alkaloid used as an antitussive agent. It is excreted in urine and can be detected as a marker of noscapine exposure. The compound is also used as a urinary detection marker for illicit opiate misuse. However, its specific in vivo pharmacological effects are not significant, as it is a metabolic breakdown product rather than an active compound. Its presence in urine provides valuable information for forensic and clinical investigations.
|
| Enzyme Assay |
In vitro enzyme/receptor binding (cell-free) assays for Meconine are not typically conducted, as it is a metabolite marker rather than a pharmacologically active compound. However, its formation from noscapine can be studied using liver microsomes or recombinant cytochrome P450 enzymes. The compound is used as a reference standard in analytical method development. All assays include appropriate controls and reference compounds.
|
| Cell Assay |
In vitro cell-based assays for Meconine are limited, as the compound is primarily used as an analytical standard. Cytotoxicity studies may be performed to assess safety. Cells are treated with compound concentrations ranging from 0.1-1000 μM for 24-72 hours. Cell viability is assessed using MTT assays. All experiments include vehicle controls.
|
| Animal Protocol |
In vivo animal studies with Meconine are limited, as the compound is a metabolite marker rather than a therapeutic agent. Pharmacokinetic studies of noscapine may measure meconine as a metabolite. Animals are administered noscapine, and urine samples are collected and analyzed for meconine. Each group consists of 6-10 animals with appropriate controls.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Meconine include its formation as a metabolite of noscapine. As a small, polar molecule, it is excreted in urine. Its presence in urine reflects noscapine exposure and metabolism. Detailed PK parameters are available from noscapine metabolism studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for Meconine are limited, as it is a metabolite marker rather than a therapeutic agent. No significant toxicity has been reported. The compound is considered safe for use as a forensic and analytical standard. As with all research chemicals, appropriate safety precautions should be taken during handling.
|
| Additional Infomation |
Meconazole belongs to the 2-benzofuran class of compounds.
Meconine (6,7-Dimethoxyphthalide) is an endogenous metabolite and a noscapine metabolite used as a urinary detection marker for illicit opiate misuse. It is a phthalide derivative belonging to the 2-benzofuran class of compounds. The compound is used as a forensic and analytical standard in toxicology and drug metabolism research. It is not approved for diagnostic or therapeutic use and is intended for research and forensic purposes only. |
| Molecular Formula |
C10H10O4
|
|---|---|
| Molecular Weight |
194.1840
|
| Exact Mass |
194.057
|
| CAS # |
569-31-3
|
| Related CAS # |
Meconin-d3;29809-15-2
|
| PubChem CID |
68437
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
404.2±45.0 °C at 760 mmHg
|
| Melting Point |
102.5 °C
|
| Flash Point |
185.1±28.8 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.548
|
| LogP |
0.63
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
14
|
| Complexity |
228
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ORFFGRQMMWVHIB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H10O4/c1-12-7-4-3-6-5-14-10(11)8(6)9(7)13-2/h3-4H,5H2,1-2H3
|
| Chemical Name |
6,7-dimethoxy-3H-2-benzofuran-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~514.99 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (12.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1499 mL | 25.7493 mL | 51.4986 mL | |
| 5 mM | 1.0300 mL | 5.1499 mL | 10.2997 mL | |
| 10 mM | 0.5150 mL | 2.5749 mL | 5.1499 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
